|   Fierce Biotech

Sanofi backs Escient’s $77.5M round as it kick-starts first clinical test

Escient Pharmaceuticals has grabbed a meaty $77.5 million series B with the help of Sanofi’s VC arm as the biotech also starts its first in-human tests. The San Diego biotech came onto the scene back in 2018 with $40 million in series A funding to develop novel G protein-coupled receptor-targeted drugs for a wide range […]

Read More
  |   San Diego Union Tribune

San Diego biotech raises $77.5M to target proteins with therapeutic potential

San Diego’s Escient Pharmaceuticals announced Monday that it has raised $77.5 million for research the company believes could lead to new treatments for certain kidney and liver disorders, among other diseases. The biotech has zeroed in on a group of proteins called G-protein coupled receptors. We have more than 700 such proteins, which regulate everything […]

Read More
  |   Endpoint News

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

A little over two years after emerging from stealth, Escient Pharmaceuticals is back Monday with a new fundraising round and their first clinical trial. The San Diego-based biotech announced a $77.5 million Series B and a Phase I/Ib study for their EP547 program, which is aiming to treat the neurological “itch” that can manifest when […]

Read More
  |   Xconomy

With $40M Banked, Escient Building for Fast Move to Human Trials

In the weeks since Escient Pharmaceuticals made its debut, the San Diego biotech has found lab space atop San Diego’s Torrey Pines Mesa and is recruiting scientists with experience developing drugs that target G protein-coupled receptors (GPCRs).

Escient’s co-founders, CEO Alain Baron and chief scientific officer Marcus Boehm, have been busy, and it took a while to catch up with them after Escient disclosed on May 9 that it has raised $40 million in Series A funding. But then, the co-founders have ambitious plans. In a recent interview with Xconomy, Baron said the initial $40 million should be enough for Escient to screen compounds for targets within a small sub-group of GPCRs, identify a lead drug candidate, and begin human clinical trials within the next three years.

Read More
  |   Chemical & Engineering News

Escient launches to tackle itching and anaphylactoid drug targets

Escient Pharmaceuticals launched today with $40 million in series A funding to develop small-molecule inhibitors of an unusual class of G protein-coupled receptors (GPCRs) implicated in chronic itching conditions. Nearly 500 U.S. FDA-approved drugs target more than 100 different GPCRs that control physiological processes as varied as appetite, blood pressure, heart rate, immune responses, mood, and […]

Read More